UK-pharmaceutical company GlaxoSmithKline (GSK) has joined with France-based venture capital investment firm Kurma Life Sciences Partners, bpifrance (France’s public investment bank), Idinvest Partners and investment fund New Enterprise Associates to launch Kurma Biofund II: The Orphan Initiative. The first closing of the fund has reached €44m ($58.2m) out of a target total of €75m ($99.3m).…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
